Search results for "Neurologia"

showing 10 items of 730 documents

Botulinum toxin type-A in the prophylactic treatment of medication-overuse headache: a multicenter, double-blind, randomized, placebo-controlled, par…

2011

Medication-overuse headache (MOH) represents a severely disabling condition, with a low response to prophylactic treatments. Recently, consistent evidences have emerged in favor of botulinum toxin type-A (onabotulinum toxin A) as prophylactic treatment in chronic migraine. In a 12-week double-blind, parallel group, placebo-controlled study, we tested the efficacy and safety of onabotulinum toxin A as prophylactic treatment for MOH. A total of 68 patients were randomized (1:1) to onabotulinum toxin A (n = 33) or placebo (n = 35) treatment and received 16 intramuscular injections. The primary efficacy end point was mean change from baseline in the frequency of headache days for the 28-day per…

AdultMalemedicine.medical_specialtyNeurologyOriginalPain medicineClinical NeurologyBotulinum toxin type-APlaceboInjections Intramuscularlaw.inventionChronic MigraineRandomized controlled trialDouble-Blind MethodlawmedicineHumansBotulinum Toxins Type AAdverse effectMuscle SkeletalBotulinum toxin type-A; Medication-overuse headache; Prophylactic treatment; Migraine; Pericranial muscle tendernessMigraineAgedAnalgesicsbusiness.industrySkullHeadacheGeneral MedicineMiddle Agedmedicine.diseaseBotulinum toxinMedication-overuse headacheAnesthesiology and Pain MedicinePericranial muscle tendernessMigraineNeuromuscular AgentsAnesthesiaSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessProphylactic treatmentmedicine.drugThe journal of headache and pain
researchProduct

Detection of possible factors favouring the evolution of migraine without aura into chronic migraine

2012

In a minority of cases, the natural history of migraine without aura (MO) is characterised over time by its evolution into a form of chronic migraine (CM). In order to detect the possible factors predicting this negative evolution of MO, we searched in our Headache Centre files for all clinical records that met the following criteria: (a) first visit between 1976 and 1998; (b) diagnosis of MO or of common migraine at the first observation, with or without association with other primary headache types; (c) <15 days per month of migraine at the first observation; and (d) at least one follow-up visit at least 10 years after the first visit. The patients thus identified were then divided into t…

AdultMalemedicine.medical_specialtyNeurologyTime FactorsAuraMigraine DisordersDermatologyYoung AdultChronic MigraineMigraine Migraine without aura Chronic migraine Chronic daily headache Chronic headacheInternal medicinemedicineHumansYoung adultDepression (differential diagnoses)business.industryDepressionGeneral MedicineMiddle Agedmedicine.diseaseComorbidityNatural historyPsychiatry and Mental healthMigraineChronic DiseaseHypertensionPhysical therapyDisease ProgressionFemaleSettore MED/26 - NeurologiaNeurology (clinical)business
researchProduct

Significant reduction of physical activity in patients with neuromuscular disease during COVID-19 pandemic: the long-term consequences of quarantine

2020

Abstract Background Quarantine was the measure taken by governments to control the rapid spread of COVID-19. This restriction resulted in a sudden change in people’s lifestyle, leading to an increase in sedentary behavior and a related decrease in the practice of physical activity (PA). However, in neuromuscular diseases patients need to perform regular PA to counteract the negative consequences of the disease. Hence, the aim of this study was to estimate the levels of PA, measured as energy expenditure (MET–minute/week), among patients with neuromuscular disease (NMD) before and during the last week of quarantine. Methods A total of 268 Italian subjects, living in Sicily, completed an adap…

AdultMalemedicine.medical_specialtyNeuromuscular diseaseCoronavirus disease 2019 (COVID-19)Physical activityCoronavirus pandemic COVID-19 Lockdown NeuromuscularPhysical activity QuarantineDiseaselaw.invention03 medical and health sciences0302 clinical medicinelawInternal medicineSurveys and QuestionnairesPandemicQuarantineLockdownmedicineHumansIn patient030212 general & internal medicineExerciseSicilyAgedCoronavirus pandemicSettore M-EDF/02 - Metodi E Didattiche Delle Attivita' SportiveOriginal Communicationbusiness.industryPhysical activitySARS-CoV-2COVID-19Neuromuscular DiseasesMiddle Agedmedicine.diseaseCross-Sectional StudiesNeurologyEnergy expenditureNeuromuscularQuarantineQuality of LifeSettore MED/26 - NeurologiaFemaleNeurology (clinical)businessSettore M-EDF/01 - Metodi E Didattiche Delle Attivita' Motorie030217 neurology & neurosurgeryJournal of Neurology
researchProduct

Optokinetic stimulation affects temporal estimation in healthy humans

2007

The representation of time and space are closely linked in the cognitive system. Optokinetic stimulation modulates spatial attention in healthy subjects and patients with spatial neglect. In order to evaluate whether optokinetic stimulation could influence time perception, a group of healthy subjects performed "time-comparison" tasks of sub- and supra-second intervals before and after leftward or rightward optokinetic stimulation. Subjective time perception was biased by the direction of optokinetic stimulation. Rightward optokinetic stimulation induced an overestimation of time perception compared with baseline and leftward optokinetic stimulation. These results indicate a directional bias…

AdultMalemedicine.medical_specialtyOptokineticgenetic structuresPhotic StimulationCognitive Neurosciencemedia_common.quotation_subjectSpatial abilitySpaceExperimental and Cognitive PsychologyStimulationNystagmusAudiologyAnalysis of Variance; Perceptual Distortion; Humans; Time Perception; Psychophysics; Photic Stimulation; Adult; Cues; Space Perception; Nystagmus Optokinetic; Attention; Female; Functional Laterality; MaleFunctional LateralityTimeNystagmusArts and Humanities (miscellaneous)Optokinetic stimulation; Perception; Space; Time; Adult; Analysis of Variance; Attention; Cues; Female; Functional Laterality; Humans; Male; Nystagmus Optokinetic; Psychophysics; Perceptual Distortion; Photic Stimulation; Space Perception; Time Perception; Cognitive Neuroscience; Experimental and Cognitive Psychology; Neuropsychology and Physiological PsychologyPerceptionDevelopmental and Educational PsychologymedicinePsychophysicsPsychophysicsHumansAttentionNystagmus Optokineticmedia_commonAnalysis of VariancePerceptual DistortionSettore M-PSI/02 - Psicobiologia E Psicologia FisiologicaCognitionSpace TimePerception Optokinetic stimulationTime perceptionNeuropsychology and Physiological PsychologySpace PerceptionTime PerceptionPerceptionFemaleSettore MED/26 - Neurologiamedicine.symptomCuesOptokinetic stimulationPsychologyPhotic StimulationCognitive psychology
researchProduct

Myocardial 123metaiodobenzylguanidine uptake in genetic Parkinson's disease.

2008

Myocardial (123)Metaiodobenzylguanidine (MIBG) enables the assessment of postganglionic sympathetic cardiac innervation. MIBG uptake is decreased in nearly all patients with Parkinson's disease (PD). Our objective was to evaluate MIBG uptake in patients with genetic PD. We investigated MIBG uptake in 14 patients with PD associated with mutations in different genes (Parkin, DJ-1, PINK], and leucine-rich repeat kinase 2 -LRRK2), in 15 patients with idiopathic PD, and 10 control subjects. The myocardial MIGB uptake was preserved in 3 of the 4 Parkin-associated Parkinsonisms, in I of the 2 patients with DJ-1 mutations, in 1 of the 2 brothers with PINK] mutations, in 3 of the 6 unrelated patient…

AdultMalemedicine.medical_specialtyParkinson's diseaseGenotypeUbiquitin-Protein LigasesDNA Mutational AnalysisProtein Deglycase DJ-1PINK1Gene mutationProtein Serine-Threonine Kinasesmedicine.disease_causeLeucine-Rich Repeat Serine-Threonine Protein Kinase-2Severity of Illness IndexParkinCentral nervous system diseaseDiagnosis DifferentialDegenerative diseaseParkinsonian DisordersInternal medicineSurveys and QuestionnairesmedicineHumansPoint MutationPromoter Regions GeneticGenetic PD Myocardial scintigraphyOncogene ProteinsTomography Emission-Computed Single-PhotonMutationMovement Disordersbusiness.industryMyocardiumIntracellular Signaling Peptides and ProteinsParkinson DiseaseGalvanic Skin ResponseMiddle Agedmedicine.diseaseLRRK2nervous system diseases3-IodobenzylguanidineEndocrinologyNeurologySettore MED/26 - NeurologiaFemaleNeurology (clinical)RadiopharmaceuticalsbusinessProtein KinasesMovement disorders : official journal of the Movement Disorder Society
researchProduct

BODY MASS INDEX DOES NOT CHANGE BEFORE PARKINSON'S DISEASE ONSET.

2008

Background and purpose:  Previous studies on the association between Parkinson’s disease (PD) and body mass index (BMI) have reported conflicting results. We investigated the relationship between PD and BMI by a case–control study. Methods:  PD patients were randomly matched to healthy individuals by sex and age. BMI distribution in cases has been compared with BMI of controls and odd ratios (ORs) with 95% CI were calculated. Results:  We included 318 PD patients and 318 controls. We observed no association between PD and BMI. BMI distribution in cases and controls was similar also when we adjusted for diabetes, hypercholesterolemia and the time elapsed between PD onset and the interview (O…

AdultMalemedicine.medical_specialtyParkinson's diseaseHypercholesterolemiaPopulationComorbidityWeight GainCoffeeBody Mass IndexRisk FactorsInternal medicineDiabetes mellitusWeight LossEpidemiologyDiabetes MellitusmedicineHumansObesityAge of OnseteducationAgedAged 80 and overHypertriglyceridemiaeducation.field_of_studybusiness.industrySmokingCase-control studynutritional and metabolic diseasesParkinson DiseaseMiddle AgedOverweightmedicine.diseaseNeurologyCase-Control StudiesHealthy individualsanthropometrical measures body mass index case–control study epidemiology Parkinson's disease risk factorsPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)businessBody mass index
researchProduct

How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire.

2008

We used a CAPSIT-based questionnaire to estimate the percentage of parkinsonian patients suitable for subthalamic nucleus (STN) deep brain stimulation (DBS) in a movement disorders clinic. We found that out of 641 consecutive PD patients only 1.6% fulfilled strict STN-DBS criteria. When we applied more flexible criteria, the percentage of eligibility increased to 4.5%. Most patients (60%) were ineligible because they did not satisfy multiple questionnaire items. Items related to disease severity were responsible for the largest number of exclusions. This knowledge will help make decisions on resource allocation in centres wishing to start DBS surgery.

AdultMalemedicine.medical_specialtyParkinson's diseaseMovement disordersNeurologyDeep brain stimulationDeep Brain Stimulationmedicine.medical_treatmentParkinson Desease Deep Brain StimulationAudiologybehavioral disciplines and activitiesDisease severityParkinsonian DisordersSubthalamic NucleusSurveys and QuestionnairesmedicineHumansAgedChi-Square Distributionbusiness.industryPatient SelectionMiddle Agedmedicine.diseasenervous system diseasesSubthalamic nucleussurgical procedures operativenervous systemNeurologyCAPSIT; Parkinson's disease; Questionnaire; STN DBS; Adult; Aged; Chi-Square Distribution; Deep Brain Stimulation; Female; Humans; Male; Middle Aged; Parkinsonian Disorders; Subthalamic Nucleus; Surveys and Questionnaires; Patient Selection; Aging; Neurology (clinical); NeurologyPhysical therapyFemaleSettore MED/26 - NeurologiaNeurology (clinical)medicine.symptomGeriatrics and GerontologyPsychologybusinesstherapeuticsNeuroscienceNeurology; Geriatrics and Gerontology; Neurology (clinical)
researchProduct

Population-based case-control study of essential tremor.

1998

Current epidemiologic data on the association between environmental factors and essential tremor (ET) are scanty. In a population-based case-control study we investigated the relationship between some putative risk factors and ET. In the present study, we included all subjects identified during a door-to-door prevalence survey in a Sicilian community, affected by ET, and alive on 1 November 1987 (n=31). Of the 31 prevalent cases of ET, we were able to contact 28 subjects. Twenty-eight controls were randomly selected from the general population and matched to each case for age and sex. Exposure variables were investigated by interviewing the patients and their controls or close relatives, us…

AdultMalemedicine.medical_specialtyPathologyEpidemiologyEssential TremorPopulationDermatologyPopulation basedOddsRisk FactorsEpidemiologymedicinePrevalenceHumanseducationAgedAged 80 and overeducation.field_of_studyNeuroscience (all)Essential tremorbusiness.industryGeneral NeuroscienceCase-control studyCase-control studyGeneral MedicineEnvironmental exposureEnvironmental ExposureMiddle Agedmedicine.diseasePsychiatry and Mental healthCase-Control StudiesSettore MED/26 - NeurologiaFemaleNeurology (clinical)Epidemiologic databusiness2708DemographyItalian journal of neurological sciences
researchProduct

Inhibition of glial proliferation in vitro by serum from patients with multiple sclerosis

1987

Primary cell cultures from fetal rat CNS have been employed to evaluate the effects caused by the addition of serum from patients affected by multiple sclerosis (MS). MS-serum supplemented media caused a decrease in [3H]-thymidine incorporation into the cultures, thus indicating an inhibitory effect on proliferating glial cells. Sera from patients in remission stage of the disease showed an inhibitory effect not significatively lower than those from patients in acute stage. These results suggest that glial cells may be a target of circulating factors present in MS.

AdultMalemedicine.medical_specialtyPathologyMultiple SclerosisDiseaseBiologyTritiumSettore BIO/19 - Microbiologia GeneraleInternal medicineSettore BIO/10 - BiochimicamedicineAnimalsHumansCells CulturedFetusNeuroscience (all)Cell growthMultiple sclerosisGeneral MedicineMiddle Agedmedicine.diseaseIn vitroAcute stageRatsEndocrinologymedicine.anatomical_structureNeurologyCell cultureNeurogliaFemaleSettore MED/26 - NeurologiaNeurology (clinical)NeurogliaCell DivisionThymidine
researchProduct

Relation between Sexual Dysfunctions and Epilepsy, Type of Epilepsy, Type of Antiepileptic Drugs: A Prospective Study

2017

Introduction The aim of this study was to evaluate the incidence of sexual dysfunctions in males with epilepsy, the type of epilepsy, the frequency of seizures, the type of antiepileptic drugs (AEDs), the serum hormonal profile and the presence of psychiatric comorbidity. Methods Sixty-one patients focused on type of epilepsy, frequency of seizures, AEDs, hormonal profile and presence of mood disorders. We excluded all patients with severe neurologic and psychiatric impairment and patient who were not able to fill questionnaires. Mean age was 31.2 years (range 18-50 years); 31 patients (50.8%) had an idiopathic generalised epilepsy and 30 (49.2%) a focal epilepsy; among them, latter 18 (60%…

AdultMalemedicine.medical_specialtyPediatricsAdolescentSexual dysfunctionSettore MED/24 - UrologiaYoung Adult03 medical and health sciencesEpilepsyTestosterone blood0302 clinical medicinemedicineHumansTestosteroneSex hormonesProspective StudiesSexual Dysfunctions PsychologicalYoung adultProspective cohort studyPsychiatryEpilepsybusiness.industryIncidenceIncidence (epidemiology)Testosterone (patch)General MedicineCarbamazepineMiddle Agedmedicine.disease030227 psychiatrySexual Dysfunction PhysiologicalCarbamazepineSexual dysfunctionAnticonvulsantsSettore MED/26 - Neurologiamedicine.symptombusiness030217 neurology & neurosurgerymedicine.drugUrologia Journal
researchProduct